Impact of COVID-19 infection in blood cancer patients

June 02, 2020

One of the first studies to investigate the outcome of COVID-19 infection in patients with blood cancer has been conducted by clinical researchers from Queen Mary University of London and Barts Health NHS Trust.

People with blood cancer are expected to be amongst those at increased risk of COVID-19 infection due to a weakened immune system from the effects of their cancer and the nature of the cancer treatment they receive.

Immunosuppression in blood cancer patients is also predicted to lead to more severe outcomes following infection. However, the present study found that even if patients were actively having intensive treatment for blood cancer that weakened their immune system, they usually recovered from COVID-19 as long as they were otherwise fit and well.

The study, published in the British Journal of Haematology, looked at 35 adult patients with blood cancer who had tested positive for COVID-19 and monitored them for a minimum of 14 days. At the end of the observation period, 60 per cent of patients had recovered from COVID-19 infection.

The observations revealed that age was the most significantly associated factor with COVID-19 infection outcome, with almost all of the patients who died being aged 70 years or older at the time of COVID-19 diagnosis. Patients who died also had significantly more co-existing health conditions, such as hypertension, chronic kidney disease or diabetes, than those who recovered from the virus.

Lead author of the study, Dr John Riches from Queen Mary University of London said: "Although this is a small and preliminary study, it is a first step in understanding the risk posed by COVID-19 to patients with blood cancers. At the current time, all patients with certain blood cancers are being advised to 'shield' to try to minimise the risk of getting the virus. However, this study suggests that the risk of COVID-19 to younger patients with few or no medical conditions aside from their blood cancer is less than the risk to older patients with lots of other medical conditions."

The data showed no correlation between blood cancer treatment and outcome following COVID-19 infection, and suggest that while patients with blood cancers have poorer outcomes than the general population after COVID-19, the majority still survive. While this is the largest study to date to examine the clinical outcome of COVID-19 infection in patients with blood cancer, the findings will need to be confirmed in large national and international registry studies.
-end-
More information

* Research paper: 'Clinical Outcome of Coronavirus Disease 2019 in Haemato?oncology Patients' by James A. Aries Jeffrey K. Davies Rebecca L. Auer Simon L. Hallam Silvia Montoto Matthew Smith Belen Sevillano Vanessa Foggo Bela Wrench Krzysztof Zegocki Samir Agrawal Rifca Le Dieu Edward Truelove Thomas Erblich Shamzah Araf Jessica Okosun Heather Oakervee Jamie D. Cavenagh John G. Gribben John C. Riches. British Journal of Haematology

Queen Mary University of London

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.